Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

autologous anti-CD20 CAR transduced CD4/CD8 enriched T cells MB-CART20.1

A preparation of autologous T lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) CD20 (cluster of differentiation 20), and CD4/CD8 enriched, with potential immunostimulating and antineoplastic activities. Upon administration, MB-CART20.1 specifically recognize and kill CD20-expressing tumor cells. The CD20 antigen, a non-glycosylated cell surface phosphoprotein, is a B-cell specific cell surface antigen expressed in B-cell lineage malignancies and certain melanoma cell subpopulations.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-CD20 CAR T cells MB-CART20.1
autologous CD20-targeted CAR-transduced CD4/CD8-enriched T cells MB-CART20.1
CD20-targeting CAR T cells MB-CART20.1
MB-CART20.1
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search